RecruitingPhase 3NCT07723248
Rare condition
Progressive muscular atrophy
76
studies recruiting now
as of 7 Sept 2026
393
studies registered in total
as of 7 Sept 2026
8
countries with a recruiting site
as of 7 Sept 2026
23 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT05861986
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
RecruitingNCT07531719
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
RecruitingPhase 1NCT06555419
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
RecruitingNot applicableNCT07521930
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 76 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Progressive muscular atrophy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Progressive muscular atrophy
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
6 approved treatments and 12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Sodium Phenylbutyrate (Ambutyrate)Approved: Nusinersen Sodium (Spinraza)Approved: Risdiplam (Evrysdi)Approved: Onasemnogene Abeparvovec (Zolgensma)Approved: Phenylbutyrate SodiumApproved: Nusinersen
Phase 3Branaplam
Phase 3Salanersen
Phase 2/3Riluzole (Exservan)
Phase 2/3Emugrobart
Phase 2Somatropin (Genotropin)
Phase 2Amifampridine Phosphate (Amifampridine serb)
Phase 2Reldesemtiv
Phase 2Apitegromab
+ 4 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).